For research use only. Not for therapeutic Use.
GW405833 hydrochloride (Cat No.: I040190) is a selective antagonist of the peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor involved in regulating genes related to metabolism, inflammation, and adipogenesis. By inhibiting PPARγ, GW405833 hydrochloride is studied for its potential to modulate metabolic processes, reduce insulin sensitivity, and alter lipid metabolism. It is often used in research to explore the role of PPARγ in conditions such as type 2 diabetes, obesity, and cardiovascular diseases, as well as to evaluate potential therapeutic applications.
| CAS Number | 1202865-22-2 |
| Synonyms | (2,3-dichlorophenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-ylethyl)indol-1-yl]methanone;hydrochloride |
| Molecular Formula | C23H25Cl3N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H24Cl2N2O3.ClH/c1-15-17(8-9-26-10-12-30-13-11-26)19-14-16(29-2)6-7-21(19)27(15)23(28)18-4-3-5-20(24)22(18)25;/h3-7,14H,8-13H2,1-2H3;1H |
| InChIKey | JIQYDHDVNNFPMU-UHFFFAOYSA-N |
| SMILES | CC1=C(C2=C(N1C(=O)C3=C(C(=CC=C3)Cl)Cl)C=CC(=C2)OC)CCN4CCOCC4.Cl |
| Reference | [1]. Li AL, Carey LM, Mackie K, Hohmann AG. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. 2017;362(2):296-305. [2]. Parlar A, Arslan SO, Doğan MF, et al. The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress. Exp Ther Med. 2018;16(6):4900-4908. [3]. Marini P, Cascio MG, King A, Pertwee RG, Ross RA. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol. 2013;169(4):887-899. [4]. Brownjohn PW, Ashton JC. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury. Neuroscience. 2012;203:180-193. |
